novo nordisk glp 1 drug Nordisk's weight-loss pill wins FDA approval Novo, Lilly buoyed by fast-growing

Description

A fresh analysis of the clinical and financial implications of comprehensive coverage in Medicare of GLP-1s for all current FDA indications (type 2 diabetes, obesity, heart disease and metabolic-associated steatohepatitis) offers some hope for long-term cost savings

most extensive Phase 3 evidence of any dual agonist

doi: 10.1038/nrcardio.2014.59 53 SarzaniRGiuliettiFDi PentimaCSpannellaF

Rising Prevalence of Diabetes and Obesity The global prevalence of type 2 diabetes, including the in the U.S., is increasing, largely due to rising rates of obesity, aging populations, and sedentary lifestyles

Mitochondria are key sites for aerobic metabolism and reactive oxygen species (ROS) production in cells and are also one of the most important organelles related to oxidative stress